progressive disease


Also found in: Acronyms.

progressive disease

Medspeak
Any chronic or dread disease (e.g., cancer), which progresses with time in scope and/or severity.

Oncology
A term defined in the context of clinical trials as tumour growth of ≥ 20% since treatment began, including local or metastatic tumour mass.

progressive disease

Medtalk A chronic or dread disease–eg, CA, which ↑ with time in scope or severity. See Dread disease.
References in periodicals archive ?
This finding is consistent with the concept that patients with progressive disease have higher disability levels and more spinal cord involvement than patients with RRMS.
Of 30 evaluable patients (excluding three patients who were not on study long enough for evaluation), in patients with progressive disease (treated for four or fewer cycles) the median disease progression free survival was 49 days (less than two months) and the median survival was 149 days (approximately five months).
CB7630 was administered once daily to chemotherapy-naove patients with hormone refractory prostate cancer (HRPC), who had progressive disease despite treatment with LHRH analogues and multiple other hormonal therapies.
7) Those with progressive disease can experience a relentless course that can end in death secondary to either respiratory or cardiac failure.
Though we've tried our best to protect him this is an incurable, progressive disease.
Because he's failed to produce the full, progressive disease in monkeys by dosing them with BMAA, he's now pursuing cycasin, another cycad compound.
David Antonio, 28, who died after a nine month battle against the new form of brain-wasting Creutzfelt-Jacob Disease, is thought to be the North of Scotland's first victim of the progressive disease.
It is a progressive disease that leads to cirrhosis and liver failure.
The new data convinces me that the proven effect in both Relapsing-Remitting disease and Secondary Progressive disease suggest that Betaseron(R) offers the potential to treat the widest range of patients -- from 0-6.
We have also promised the FDA that we will follow up on our intention to study Avonex in secondary progressive disease, but the details of a trial are not yet set.
Previous study data presented by diaDexus at the 2005 San Antonio Breast Cancer Symposium demonstrated that a set of eight genes were differentially expressed in patients who presented with progressive disease, compared with those who were disease-free after a median follow-up of 70 months, suggesting that the PCR-based test involving these genes warrants additional investigation into its utility in identifying patients at higher risk for recurrence.

Full browser ?